A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer

Journal of Clinical Oncology

Volumn 25, Issue 24, 2007, Pages 3576-3581

  Walz, Jochen ^a   Gallina, Andrea ^a   Saad, Fred ^a   Montorsi, Francesco ^a   Perrotte, Paul ^a   Shariat, Shahrokh F ^a   Jeldres, Claudio ^a   Graefen, Markus ^a   Bénard, Francois ^a   McCormack, Michael ^a   Valiquette, Luc ^a   Karakiewicz, Pierre I ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BOOTSTRAPPING; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; DECISION MAKING; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; LIFE EXPECTANCY; MALE; MODELS, STATISTICAL; NOMOGRAMS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 34548504813     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.3820     Document Type: Article

References (29)

1. Aus G, Abbou CC, Bolla M, et al: EAU guidelines on prostate cancer. Eur Urol 48:546-551, 2005
2. Middleton RG: The management of clinically localized prostate cancer: Guidelines from the American Urological Association. CA Cancer J Clin 46: 249-253, 1996
3. Scardino P: Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Cane Netw 3:S29-S33, 2005 (suppl 1)
4. Statistics Canada. www.statcan.ca
5. Arias E: United States life tables, 2003. Natl Vital Stat Rep 54:1-40, 2006
6. Albertsen PC, Fryback DG, Storer BE, et al: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274:626-631, 1995
7. Albertsen PC, Hanley JA, Fine J: 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101, 2005
8. Chow E, Davis L, Panzarella T, et al: Accuracy of survival prediction by palliative radiation oncologists. Int J Radiat Oncol Biol Phys 61:870-873, 2005
9. Henderson R, Jones M, Stare J: Accuracy of point predictions in survival analysis. Stat Med 20: 3083-3096, 2001
10. Cowen ME, Halasyamani LK, Kattan MW: Predicting life expectancy in men with clinically localized prostate cancer. J Urol 175:99-103, 2006
11. Tewari A, Johnson CC, Divine G, et al: Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol 171:1513-1519, 2004
12. Albertsen PC, Fryback DG, Storer BE, et al: The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 156:127-132, 1996
13. Karakiewicz PI, Bazinet M, Aprikian AG, et al: Thirty-day mortality rates and cumulative survival after radical retropubic prostatectomy. Urology 52: 1041-1046, 1998
14. Karakiewicz PI, Zini A, Meshref AW, et al: Population-based patterns of radical retropubic prostatectomy use. Urology 52:219-223, 1998
15. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
16. Hall WH, Jani AB, Ryu JK, et al: The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 8:22-30, 2005
17. D'Hoore W, Sicotte C, Tilquin C: Risk adjustment in outcome assessment: The Charlson comorbidity index. Methods Inf Med 32:382-387, 1993
18. Harrell Jr FE, Califf RM, Pryor DB, et al: Evaluating the yield of medical tests. JAMA 247: 2543-2546, 1982
19. Harrell Jr FE, Lee KL, Mark DB: Multivariate prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
20. Ruchlin HS, Pellissier JM: An economic overview of prostate carcinoma. Cancer 92:2796-2810, 2001
21. Kattan MW: Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: Preoperative application in prostate cancer. Curr Opin Urol 13:111-116, 2003
22. Arredondo SA, Elkin EP, Marr PL, et al: Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: Data from CaPSURE. Urology 67:559-565, 2006
23. Alibhai SM, Krahn MD, Cohen MM, et al: Is there age bias in the treatment of localized prostate carcinoma? Cancer 100:72-81, 2004
24. Bubolz T, Wasson JH, Lu-Yao G, et al: Treatments for prostate cancer in older men: 1984-1997. Urology 58:977-982, 2001
25. Harlan LC, Potosky A, Gilliland FD, et al: Factors associated with initial therapy for clinically localized prostate cancer: Prostate cancer outcomes study. J Natl Cancer Inst 93:1864-1871, 2001
26. Yan Y, Carvalhal GF, Catalona WJ, et al: Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 88:1122-1130, 2000
27. Fowler Jr FJ, McNaughton Collins M, Albertsen PC, et al: Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 283:3217-3222, 2000
28. Fowler Jr JE, Terrell FL, Renfroe DL: Comorbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 156:1714-1718, 1996
29. Steyerberg EW, Harrell Jr FE, Borsboom GJ, et al: Internal validation of predictive models: Efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54:774-781, 2001